Organization
Tennessee Oncology, PLLC
40 abstracts
2 posters
Poster
MCLA-129-CL01Abstract
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Tennessee Oncology, PLLC, University General Hospital of Heraklion, Hospital de Cancer de Londrina, Baskent University Faculty of Medicine, Mater Adult Hospital Brisbane,
Abstract
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Daiichi Sankyo Inc., Rutgers Cancer Institue of New Jersey, Highlands Oncology, Washington University School of Medicine,
Abstract
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,
Abstract
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).Org: Prelude Therapeutics Incorporated, Washington University School of Medicine, Sarah Cannon Research Institute at HealthONE, Florida Cancer Specialists/Sarah Cannon Research Institute, Prelude Therapeutics, Inc.,
Abstract
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.Org: Laura and Isaac Perlmutter Cancer Center, Sir Charles Gairdner Hospital, Washington University Oncology, Sarah Cannon Research Institute/Tennessee Oncology, One Clinical Research and Edith Cowan University,
Abstract
Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.Org: The West Cancer Center, OneOncology, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Flatiron Health, San Francisco, CA,
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.Org: Pfizer Inc., European Institute of Oncology IRCCS, National Cancer Center Hospital East, Kashiwa, Japan, Guangdong Lung Cancer Institute, Tennessee Oncology, PLLC,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania, Tennessee Oncology, PLLC,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
Assessing the true cost of cancer screening: Comparing hospital prices to claims remittance data for common cancer screening tests at top-ranked US hospitals.Org: Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Tennessee Oncology, PLLC, Owen Graduate School of Management,
Abstract
Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results.Org: Division of Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Tennessee Oncology, PLLC, Sarah Cannon Research Institute, Nashville, TN, Sarah Cannon Research Institute at HealthONE, Denver, CO, NEXT Oncology Virginia, Fairfax, VA,
Abstract
Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS).Org: Tennessee Oncology, PLLC, Chattanooga, TN, Nashville, West Cancer Center & Research Institute,
Abstract
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.Org: Next Oncology Virginia and Virginia Cancer Specialists, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Cancer Center Hospital East, Kashiwa, Japan, Cedars-Sinai Cancer Institute,
Abstract
Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), State Key Laboratory of South China,
Abstract
Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.Org: James Thoracic Oncology Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Columbus, OH, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Cell Therapy Manufacturing Center, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Cell Therapy Manufacturing Center, a joint venture between MD Anderson Cancer Center and Resilience,
Abstract
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at Florida Cancer Specialists, Hackensack Meridian Health, START San Antonio, University of Navarra, Carolina BioOncology Institute,
Abstract
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, NEXT Oncology - Virginia Cancer Specialists, University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute,
Abstract
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Virginia Cancer Specialists, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Summit Cancer Centers, Spokane Valley, WA, Virginia Cancer Specialists, Perlmutter Cancer Center at NYU Langone Health Medical Center,
Abstract
Association of participation in Medicare’s Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysis.Org: Memorial Sloan Kettering Cancer Center, Elevance Health, Humana, CVS Health, Texas A&M University,
Abstract
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.Org: Honor Health, Parkview Physician Group, Parkview Cancer Institute, Summit Cancer Centers, Spokane Valley, WA, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Henry Ford Cancer Institute, Detroit, MI, University of Colorado Denver Anschutz Medical Center, Dana-Farber Cancer Institute,
Abstract
MyTACTIC: Afficacy and safety of atezolizumab (atezo) + chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, OneOncology, Inc., New York Cancer and Blood Specialists,
Abstract
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma.Org: Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Florida Cancer Specialists, University of California Irvine, Del Mar Pharmaceuticals, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
A phase 1/2, first-in-human trial of ZB131, a novel antibody targeting cancer-specific plectin (CSP) in advanced solid tumors.Org: Next Oncology Virginia and Virginia Cancer Specialists, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Mary Crowley Cancer Research Center, Tennessee Oncology, PLLC, BCCA, Sindi Ahluwalia Hawkins Centre for the Southern Interior,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.Org: Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Nashville, TN, EQRx, Cambridge, MA,
Abstract
A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.Org: University of Tennessee Medical Center at Knoxville, Orlando Health Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, St. John's Cancer Institute, Santa Monica, CA,
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,
Abstract
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.Org: Lung Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Sarah Cannon Research Institute at HealthONE, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Intravenous (IV) infusion of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, as monotherapy in advanced solid tumors: Preliminary results from an ongoing phase 1/2a study.Org: Banner MD Anderson Cancer Center, Mary Crowley Cancer Research Center, Virginia Health Specialists, Fairfax, VA, Prisma Health Cancer Institute, ImmVira Co., Limited,